CardioVascular and Interventional Radiology (CVIR) is an official journal of
the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
Founded in 1978 by Professors Herbert L. Abrams and Eberhard Zeitler,
CVIR is the longest-running journal in the field of vascular and interventional radiology.
CIRSE Members have unlimited online access to all CVIR articles. To access the full text articles, log in with the credentials for myCIRSE.
CVIR’s November issue features a special section on MSK interventions curated by world-renown expert in the field: Julien Garnon.
This special section presents the latest technical advancements and most significant data from the literature on hot topics in MSK. The goal is to give any IR an overview of what is feasible and
for which result.
Endovascular treatment has an established role in the successful management of visceral and renal artery aneurysms and pseudoaneurysms, and this Standards of Practice document provides up-to-date recommendations for its safe performance.
Optimize your article with the new feature in CVIR! Submit a visual abstract of your paper in addition to the textual abstract, to highlight your research and findings. All article types are eligible, with the exception of editorials, letters to the editor and commentaries. Click here to download the template.
We are happy to announce CVIR’s 2022 impact factor which increased to 2.9! This achievement underscores the exceptional quality and importance of the articles published in the journal. A big thank you to the journal’s dedicated authors, reviewers, editors, and readers for their invaluable contributions and support.
Thank you for your participation in CVIR activities at CIRSE 2023! As always, we had a great time with you and look forward to our next gathering.
Clean the veins! Outcomes from the CLOUT registry on 499 patients from 43 US sites that were treated with mechanical thrombectomy for deep venous thrombosis confirms satisfactory outcomes with significant improvement in symptoms and patients’ health status. Freedom from re-thrombosis at six months was >90%. Adverse events rate was low but there was one device related death due to fatal PE.
Are you about to submit your paper to CVIR?
Click here to find out which biological/biomedical reporting checklists are mandatory when submitting to CVIR.
2-year impact factor |
2.9 | |
5-year impact factor |
2.6 | |
Downloads in 2022 |
591,937 | |
Days to first decision (2022 median) |
5 days |